Mark T Iwicki sold $125k of KALA
CHIEF EXECUTIVE OFFICER at KALA BIO, Inc.. 154,894 shares at an average of $0.81, traded Oct 23, 2025, filed Oct 24, 2025.
Score components
- +15RoleDirector
- +11Trade size$125k at market
- +20Share of holdings soldSold 60% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415537-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 23, 2025 | SOpen-market sale Common Stock | -154,894 | $0.81 | $125k | 103,540 | Oct 24, 2025 |
Related signals
Other insiders at KALA BIO, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | KALA BIO, Inc. | Todd Bazemore SEE REMARKS | $40k 47,768 shares | -57% | |
| 56Moderate | KALA BIO, Inc. | Romulus K Brazzell SEE REMARKS | $39k 46,748 shares | -57% | |
| 62Notable | KALA BIO, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $28k 33,197 shares | -53% | |
| 40Moderate | KALA BIO, Inc. | Darius Kharabi CHIEF BUSINESS OFFICER | $17k 20,806 shares | -33% | |
| 53Moderate | KALAsell KALA BIO, Inc. | Baker Bros. Advisors LP other | $1.1M 730,408 shares | -616% | |
| 10Weak | KALA BIO, Inc. | Todd Bazemore SEE REMARKS | $16k 4,058 shares | -5% | |
| 10Weak | KALA BIO, Inc. | Romulus K Brazzell SEE REMARKS | $21k 5,251 shares | -6% | |
| 17Weak | KALA BIO, Inc. | Mark T Iwicki CHIEF EXECUTIVE OFFICER | $53k 13,227 shares | -5% | |
| 17Weak | KALA BIO, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $15k 3,631 shares | -6% | |
| 10Weak | KALA BIO, Inc. | Darius Kharabi CHIEF BUSINESS OFFICER | $18k 4,511 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.